Vinoth Rajendran

List of Publications by Citations

21 papers	361 citations	11 h-index	19 g-index
24 ext. papers	449 ext. citations	3.9 avg, IF	3.53 L-index

#	Paper	IF	Citations
21	Purification and characterization of a novel and robust L-asparaginase having low-glutaminase activity from Bacillus licheniformis: in vitro evaluation of anti-cancerous properties. *PLoS ONE*, **2014** , 9, e99037	3.7	82
20	Stearylamine Liposomal Delivery of Monensin in Combination with Free Artemisinin Eliminates Blood Stages of Plasmodium falciparum in Culture and P. berghei Infection in Murine Malaria. *Antimicrobial Agents and Chemotherapy*, **2015**, 60, 1304-18	5.9	35
19	Enhanced efficacy of anti-miR-191 delivery through stearylamine liposome formulation for the treatment of breast cancer cells. *International Journal of Pharmaceutics*, **2017**, 530, 387-400	6.5	32
18	Design, synthesis and biological evaluation of functionalized phthalimides: a new class of antimalarials and inhibitors of falcipain-2, a major hemoglobinase of malaria parasite. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 1817-27	3.4	31
17	Cell mediated immune response after challenge in Omp25 liposome immunized mice contributes to protection against virulent Brucella abortus 544. *Vaccine*, **2013**, 31, 1231-7	4.1	28
16	Synthesis and Antimalarial Evaluation of [1, 2,3]-Triazole-Tethered Sulfonamide-Berberine Hybrids. *ChemistrySelect*, **2018**, 3, 9790-9793	1.8	26
15	Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use. *European Journal of Pharmaceutical Sciences*, **2020**, 142, 105159	5.1	25
14	Protective effect of galangin against dextran sulfate sodium (DSS)-induced ulcerative colitis in Balb/c mice. *Inflammation Research*, **2019**, 68, 691-704	7.2	20
13	Hydroxyethylamine Based Phthalimides as New Class of Plasmepsin Hits: Design, Synthesis and Antimalarial Evaluation. *PLoS ONE*, **2015**, 10, e0139347	3.7	17
12	Antiplasmodial activity of hydroxyethylamine analogs: Synthesis, biological activity and structure activity relationship of plasmepsin inhibitors. *Bioorganic and Medicinal Chemistry*, **2018**, 26, 3837-3844	3.4	15
11	Fast-Acting Small Molecules Targeting Malarial Aspartyl Proteases, Plasmepsins, Inhibit Malaria Infection at Multiple Life Stages. *ACS Infectious Diseases*, **2019**, 5, 184-198	5.5	11
10	Improved efficacy of doxycycline in liposomes against Plasmodium falciparum in culture and Plasmodium berghei infection in mice. *Canadian Journal of Physiology and Pharmacology*, **2018**, 96, 1145-1152	2.4	7
9	Synergistic blending of high-valued heterocycles inhibits growth of Plasmodium falciparum in culture and P. berghei infection in mouse model. *Scientific Reports*, **2017**, 7, 6724	4.9	7
8	Chemotherapeutic Potential of Monensin as an Anti-microbial Agent. *Current Topics in Medicinal Chemistry*, **2018**, 18, 1976-1986	3	6
7	Preclinical Evidence of Nanomedicine Formulation to Target at Its Bone Marrow Niche. *Pathogens*, **2020**, 9,	4.5	4
6	Synthesis, characterization, and antiplasmodial efficacy of sulfonamide-appended [1,2,3]-triazoles. *Journal of Heterocyclic Chemistry*, **2020**, 57, 1625-1636	1.9	4
5	Multistage antiplasmodial activity of hydroxyethylamine compounds, in vitro and in vivo evaluations. *RSC Advances*, **2020**, 10, 35516-35530	3.7	4

List of Publications

4	Combinatorial Effects of Monensin in Liposome Formulations with Antimalarial Drugs Against Blood Stages of Plasmodium falciparum in Culture and P. berghei Infection. *Current Drug Therapy*, **2018**, 13, 74-82	0.7	3
3	Synthesis and Evaluation of Antiplasmodial Activity of 2,2,2-Trifluoroethoxychalcones and 2-Fluoroethoxy Chalcones against Plasmodium falciparum in Culture. *Molecules*, **2018**, 23,	4.8	2
2	Assessment of anti-plasmodial activity of non-hemolytic, non-immunogenic, non-toxic antimicrobial peptides (AMPs LR14) produced by Lactobacillus plantarum LR/14. *Drugs in R and D*, **2014**, 14, 95-103	3.4	2
1	Mammalian host microRNA response to plasmodial infection: role as therapeutic target and potential biomarker. *Parasitology Research*, **2021**, 120, 3341-3353	2.4	